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Studying the metabolism of immune cells in recent years has emphasized the tight link
existing between the metabolic state and the phenotype of these cells. Macrophages in
particular are a good example of this phenomenon. Whether the macrophage obtains its
energy through glycolysis or through oxidative metabolism can give rise to different pheno-
types. Classically activated or M1 macrophages are key players of the first line of defense
against bacterial infections and are known to obtain energy through glycolysis. Alterna-
tively activated or M2 macrophages on the other hand are involved in tissue repair and
wound healing and use oxidative metabolism to fuel their longer-term functions. Metabolic
intermediates, however, are not just a source of energy but can be directly implicated in
a particular macrophage phenotype. In M1 macrophages, the Krebs cycle intermediate
succinate regulates HIF1α, which is responsible for driving the sustained production of
the pro-inflammatory cytokine IL1β. In M2 macrophages, the sedoheptulose kinase car-
bohydrate kinase-like protein is critical for regulating the pentose phosphate pathway. The
potential to target these events and impact on disease is an exciting prospect.
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INTRODUCTION
Early insights into the metabolic status of macrophages date back
to the pioneering work carried out by G. C Hard more than 40 years
ago. Hard showed that activated murine peritoneal macrophages
had lower levels of oxygen consumption than resting ones as well
as higher levels of glycolysis (1). This study provided the first evi-
dence of a significant metabolic change in the macrophage as a
consequence of activation. Studies by Newsholme and colleagues
in the 1980s provided further evidence supporting this idea, as
they were able to show that enzymes involved in glucose metabo-
lism have higher enzymatic activities in macrophages, resulting in
high rates of glucose and glutamine consumption (2).
Shortly afterward, in the early 1990s, a role for IL4 in
macrophage activation was described, as well as the concept of
alternative activation (3, 4). At this stage, a distinction was made
between classically activated macrophages, also known as M1,
and alternatively activated macrophages, also referred to as M2.
M1 macrophages are activated by bacterial-derived products such
as lipopolysaccharide (LPS), as well as by signals associated with
infection such as IFNγ. This type of activation results in a highly
inflammatory macrophage with high phagocytic and bactericidal
potential. M2 macrophages on the other hand can be activated
by parasitic products as well as signals associated with parasitic
infections, such as the cytokines IL4 and IL13. This gives rise to a
macrophage with anti-parasitic and tissue repair functions (5).
Also during this period, further research was carried out on the
metabolic changes associated with macrophage activation. Bus-
tos and Sobrino suggested for the first time that the inhibition
of cytokine production in macrophages caused by glucocorti-
coids could be due to the inhibition of the glycolytic enzymes
PFK1 and PFK2, thus directly implicating impaired metabolism
with impaired function (6). A key discovery was, however, in argi-
nine metabolism. Inés María Corraliza and colleagues were able
to show that different enzymes responsible for the metabolism of
arginine would be induced in a macrophage depending on the
type of activation. In an M1 macrophage, nitric oxide synthase
(iNOS) is upregulated, resulting in the catabolism of arginine to
citrulline and nitric oxide, the latter playing key role in the intra-
cellular killing of pathogens. In an M2 macrophage on the other
hand,arginase-1 (Arg1) is induced, which results in the production
of urea, polyamines, and ornithine, which are important for the
wound healing actions of this macrophage population (7, 8). The
differential metabolism of arginine is as of today, one of the most
reliable discriminating factors between M1 and M2 macrophages.
In fact, it is the only factor identified so far that can be used to detect
M2 macrophage polarization in human samples (9). This provides
an example of how studying the metabolic status of macrophages
has proven more useful than studying function alone as well as
unveiling the potential for therapeutic targeting in disease.
GLYCOLYTIC M1 VERSUS OXIDATIVE M2 MACROPHAGES
Although studies into the metabolism of immune cells date back
a few decades, it has only been in recent years that the tight link
between metabolism and function has become apparent. The clear
metabolic differences existing between M1 and M2 macrophages
exemplify this idea. An M1 macrophage is part of the first line of
defense of the innate immune system, which takes place within
hours to days, as opposed to an M2 macrophage, which plays a
bigger role within the resolution phase and thus has longer-term
functions. Their metabolism is unsurprisingly a clear reflection of
those functions.
In M1 macrophages, aerobic glycolysis is induced upon activa-
tion, which involves an increase in glucose uptake as well as the
conversion of pyruvate to lactate (Figure 1). At the same time,
the activities of the respiratory chain are attenuated, allowing
for reactive-oxygen species (ROS) production. Further evidence
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FIGURE 1 | Metabolic profile of an M1 macrophage is shown.
Classically activated macrophages induce an aerobic glycolytic program
that results in lactate production and increased levels of intermediates of
the Krebs cycle. The HIF1α transcription factor also becomes activated
and can drive production of pro-inflammatory cytokines. The key
functional consequences are bacterial killing, mostly through the
production of ROS and NO, and inflammation, which occurs via cytokine
production. G6P, glucose-6-phosphate; F6P, fructose-6-phosphate; R5P,
ribulose-5-phosphate; S7P, sedoheptulose phosphate; NO, nitric oxide;
ROS, reactive-oxygen species.
for this is provided when treating macrophages with the elec-
tron transport chain inhibitors rotenone and antimycin A as this
mimics the effects of toll-like receptor (TLR) agonists in driving
ROS production from the mitochondria (10). Furthermore, the
pentose phosphate pathway is also induced following classical acti-
vation. This pathway is key for the generation of NADPH for the
NADPH oxidase, which is important for ROS production, but also
for nitric oxide synthesis (11). Altogether, these metabolic events
can provide the cell with rapid energy and reducing equivalents,
which are required for bactericidal activity. M2 macrophages on
the other hand obtain much of their energy from fatty acid oxida-
tion and oxidative metabolism, which can be sustained for longer.
Following activation, they can induce expression of constituents
of the electron transport chain that will perform oxidative phos-
phorylation as well as driving the pyruvate into the Krebs cycle
(Figure 2). The pentose phosphate pathway is also more limited in
M2 macrophages. Blocking oxidative metabolism not only blocks
the M2 phenotype but also drives the macrophage into an M1 state.
Similarly, forcing oxidative metabolism in an M1 macrophage
potentiates the M2 phenotype (12, 13). These key metabolic dif-
ferences between differentially activated macrophages are widely
accepted; however, the switches responsible for orchestrating these
different profiles at the molecular level remain largely unknown
and how exactly the cell’s metabolic status regulates polarization
is not yet well understood.
Following classical activation, there is a switch in the expres-
sion of 6-phosphofructose-2-kinase/fructose-2,6-bisphosphatase
(PFK2) isoforms from the liver-form (L-PFK2) to the more active
ubiquitous form (u-PFK2), leading to fructose-2,6-bisphosphaste
accumulation, which pushes the glycolytic flux. This switching
occurs at the transcriptional level with the L-PFK2 gene, PFKB3,
being induced following activation (12). Additionally, there seems
to be a requirement for downregulation of the carbohydrate
kinase-like protein (CARKL) for the development of an M1
phenotype. CARKL catalyzes the production of sedoheptulose-
7-phosphate, an intermediate of the pentose phosphate pathway
(Figure 1). Besides expression levels of CARKL rapidly decreas-
ing following classical activation, CARKL-expressing cells show
defects in LPS-induced superoxide production. Furthermore,
overexpression of CARKL results in a decrease in the produc-
tion of pro-inflammatory cytokines in accordance with an M2
phenotype. Altogether, this would suggest that CARKL may help
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FIGURE 2 | Metabolic profile of an M2 macrophage is shown. Alternatively
activated macrophages trigger a metabolic program including the electron
transport chain as well as fatty acid β-oxidation, which is orchestrated by
STAT6 and PGC-1β. Arg1 also drives the production of polyamines and
ornithine. The key functional consequences are tissue repair and anti-parasitic
responses.
drive the macrophage metabolism toward increased pentose phos-
phate pathway activity and increased redox state, thus supporting
M1 polarization (14). Finally, activation of macrophages with LPS
results in increased levels of Krebs cycle intermediates such as suc-
cinate and malate. Succinate, in particular, was shown to drive IL1β
production through HIF1α, a response that could be blocked by
inhibition of glycolysis using 2-deoxyglucose (15). This exempli-
fies how the macrophage metabolism is not simply needed for pro-
viding the energy required but can also have a direct involvement
in the transcriptional regulation of the immune response.
Following alternative activation, the PFKB1 gene instead of the
PFKB3 is expressed, resulting in higher levels of the liver isoform
of PFK2 and lower levels of fructose-2,6-bisphosphate. The lower
glycolytic levels are compensated with an increase in oxidative
phosphorylation. Following macrophage activation with IL4, there
is massive induction of an oxidative metabolic program, ranging
from fatty acid uptake and oxidation, to oxidative phosphoryla-
tion and mitochondrial respiration. The mechanism behind this
increase is somewhat better understood than that of glycolysis in
M1 macrophages. Following IL4 treatment, the transcription fac-
tor STAT6, which is responsible for mediating the transcriptional
responses of this cytokine, becomes activated. Active STAT6 can
induce the coactivator protein peroxisome proliferator-activated
receptor (PPAR)γ-coactivator-1β (PGC-1β). PGC-1β can induce
mitochondrial respiration as well as mitochondrial biogenesis.
Furthermore, together with the transcription factors, nuclear res-
piratory factor 1 (NRF-1) and estrogen-related receptor-α (ERRα),
it drives the production of key mitochondrial components, such
as cytochrome c and ATP synthase (16, 17). It is therefore not
surprising that PGC-1β is considered as the key player responsible
for the metabolic switch in M2 macrophages (Figure 2). In fact,
knockdown of PGC-1β impairs not only the metabolic profile of
M2 macrophages but also their functions (13). Furthermore, while
PGC-1β is the key trigger, PPARs, particularly PPARγ and PPARδ,
have a key role in maintaining the phenotype. PPARδ is responsible
for orchestrating the effector functions of alternative activation,
for instance, expression of the macrophage galactose-type C-type
lectin 1 (MGL-1) as well as costimulatory molecules and other
factors involve in the anti-inflammatory response. PPARγ on the
other hand, is involved in the transcription of different factors
required for β-oxidation of fatty acids (18, 19).
Recently, the protein TNF-alpha-induced protein 8-like 2
(TIPE2) has also been associated with an M2 phenotype, through
the induction of arginine metabolism, which as already men-
tioned, is the most distinguished metabolic feature of M2
macrophages. Interestingly, TIPE2 exerts such function follow-
ing long-term classical activation of macrophages with LPS and
not alternative activation. Thus, TIPE2 uses the switching to argi-
nine metabolism to negatively regulate inflammation, and can
therefore re-program a classically activated macrophage into its
anti-inflammatory counterpart (20).
HYPOXIA-INDUCIBLE FACTOR IN MACROPHAGE
POLARIZATION
Macrophages, as well as other immune cells, are usually found in
inflamed sites, which are characterized by low oxygen levels. The
transcription factor HIF thus plays an important role as one of
the key mediators in the adaptation of macrophages to hypoxic
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conditions. This heterodimeric protein is composed of two sub-
units, an α and a β subunit. Three isoforms of the oxygen-sensitive
α subunit have been identified. The HIF1α isoform is expressed
ubiquitously, and is tightly linked to the inflammatory response
and microbicidal activities. HIF2α on the other hand, is expressed
in a more limited fashion, but it is present in myeloid cells (21,
22). There is evidence in the literature suggesting a role for the two
HIFα isoforms, 1 and 2, in macrophage polarization. While HIF1α
has been associated with classical macrophage activation, HIF2α
has been recently linked to an M2 phenotype. These differential
roles are, however, far from clear.
HIF1α expression can be driven by different classical activators
through NF-κB, resulting in the production of pro-inflammatory
cytokines and other mediators of the M1 phenotype, such as gly-
colytic enzymes and glucose transporters. HIF2α expression, on
the other hand, occurs independently of NF-κB, which would be in
accordance with alternative activation. Interestingly though, both
isoforms seem to be important in maintaining levels of the NF-
κB subunit p65 (23). A key mediator regulated by HIF1α is the
M1 marker iNOS. Under hypoxic conditions, nitric oxide produc-
tion through iNOS is HIF1α-dependent thus implicating HIF1α
in bacterial clearance (24). In fact, HIF1α−/− macrophages have
impaired capacity to clear both Gram-positive and Gram-negative
bacteria. Nevertheless, superoxide production during the respira-
tory burst, which is also required for bacterial clearance, seems
to be a HIF1α-independent event (25). This is, interestingly, not
the only HIF1α-independent event that occurs following classical
activation. A critical event in the reprograming of metabolism to
glycolysis is the switch from L-PFK2 to u-PFK2, which also occurs
independently of HIF1α (12). This would suggest the presence of
some other yet unidentified factor responsible for mediating the
metabolic switch in M1 macrophages, either independently or in
association with HIF1α.
The potential role of HIF2α in promoting the M2 phenotype,
although promising, remains obscure. HIF2α has been shown to
regulate transcription of the M2 marker, Arg1. This finding is
supported by the half-life of both proteins, as both the mRNAs
for HIF2α as well as Arg1, have relatively long half-lives. The
mRNAs for HIF1α and iNOS, however, are relatively short-lived
(24). This would agree with the initial idea of how the metabo-
lism of polarized macrophages goes hand in hand with the timing
of their functions, and would support the association of HIF1α
and HIF2α with M1 and M2 macrophages, respectively. There are,
however, incongruences regarding the role of HIF2α. For instance,
HIF2α also controls IL1β production, which is associated with an
M1 phenotype rather than M2 (15). Additionally, HIF2α has also
been associated with NF-κB activity as mentioned above, which is
also associated with an M1 phenotype (23). Studies have shown,
however, that both isoforms seem to have redundant and over-
lapping functions, even though when one is knocked down, the
other does not seem to be able to compensate (23). This highlights
the fact that there are still major gaps in our understanding of the
differential activities of the two isoforms.
POLARIZATION OF HUMANMACROPHAGES
Most current knowledge of macrophage polarization comes from
murine studies; however,our understanding of this topic in human
macrophages remains quite poor. Furthermore, the limited studies
that have been carried out using human macrophages have identi-
fied major interspecies differences. For instance, classic murine
M2 macrophage markers, such as Ym1 or Fizz1, lack human
homologs and can therefore not be used as markers in human
macrophages (26).
Interestingly, a recent proteomic analysis of differentially acti-
vated human macrophages suggests that the major functional dif-
ferences between the two lie within metabolic pathways. The study
identifies major metabolic enzymes such as glucose-6-phosphate
dehydrogenase, fructose-1,6-bisphosphatase 1 (Fbp1), alpha eno-
lase, and fructose bisphosphate aldolase A as being differentially
expressed in human M1 and M2 macrophages (27). In agreement
with murine studies, human M1 macrophages also upregulate gly-
colysis to give rise to a pro-inflammatory phenotype characterized
by the production of cytokines such as IL12p40, TNFα, or IL6.
However, oxidative metabolism and fatty acid oxidation do not
seem to predominate in human M2 macrophages, but instead,
gluconeogenesis, driven by Fbp1, seems to play a major role (27).
This finding is supported by a subsequent study suggesting that
fatty acid oxidation is dispensable in human M2 macrophages.
D. Namgaladze and B. Brüne show that IL4-induced human M2
macrophages do not induce PGC-1β, the key transcription fac-
tor responsible for driving the fatty acid oxidation program. In
contrast with murine studies, the use of a fatty acid oxidation
inhibitor does not impair the ability of human macrophages to
produce high levels of CCL18 and Mrc1 and low levels of IL1-β
and IL6, suggesting that they maintain the M2 phenotype (28).
Another major aspect that seems to differ considerably between
murine and human macrophages is the role of iNOS and Arg1
in M1 and M2 macrophages, respectively. Attempts to demon-
strate significant production of NO by human macrophages in
culture have mostly failed. When successfully detected, it has only
been after a period of stimulation of a few days and in much
smaller amounts than that detected in murine macrophages (29).
Furthermore, a recent report indicates that epigenetic modifica-
tions silence the nos2 gene in humans, suggesting that there is
no role for iNOS in M1-mediated inflammation (30). Intrigu-
ingly, macrophage-derived NO production has been reported in
cases of acute inflammation such as those presented by rheuma-
toid arthritis patients as well as those suffering from malaria (31,
32). On the other hand, it is not just the role of iNOS that has
been questioned, but also that of Arg1. Neither Cameron et al. nor
Sheemann et al. could detect any arginase activity from human
macrophages in culture (33, 34). However, Anika Geelhaar-Karsch
and colleagues have recently shown that patients suffering from
classical Whipple’s disease, which is associated with elevated levels
of M2 macrophages, present with higher levels of arginase activity
as well as Arg1-derived products, such as urea (9). Interestingly,
this could only be detected in plasma and fresh biopsies and not in
macrophages in culture. Therefore, although the major differences
existing between mice and humans in this regard are undisputable,
the switch toward iNOS versus Arg1 may still play an important
role in human diseases.
FINAL PERSPECTIVES
The metabolic aspects behind macrophage activation have long
been an area of interest for many. Metabolism as a key aspect
of macrophage polarization, however, is an intriguing area within

























































Galván-Peña and O’Neill Metabolic reprogramming in macrophage polarization
macrophage biology that has only started to develop more recently.
Although we are still very much in the dark regarding our under-
standing of the metabolic molecular events driving macrophage
polarization, the evidence discussed suggests that the role of meta-
bolic intermediates is much more important than expected. The
key question is why M1 and M2 macrophages would have such
different metabolic profiles? It is possible that M1 macrophages
are mainly found in hypoxic environments and therefore have to
rely on glycolysis, produced via HIF1α, for their ATP production.
Glycolysis can also be rapidly induced, which is perhaps needed for
the rapid activation that occurs in M1 macrophages during infec-
tion. The attenuation in the respiratory chain will also allow M1
macrophages to produce ROS, as will the NADPH produced by
the pentose phosphate pathway, which is required for the NADPH
oxidase. For M2 macrophages, acute activation is less of an issue, as
their main function is in wound healing and anti-parasitic defense.
M2 macrophages also do not generate ROS and therefore have a
fully functional respiratory redox chain, allowing for oxidation
of fatty acids. β-oxidation of fatty acids has, in fact, been shown
to be anti-inflammatory, possibly because of a decrease in the
production of prostaglandins, although this is not fully under-
stood (35). Perhaps, the more sustained role of M2 macrophages
mainly involves the metabolism of fat reserves with less ROS being
a safe-ground against injury during tissue repair.
The translation of these discoveries to human diseases is an
intriguing prospect, especially, since there are diseases that have
been associated with one particular macrophage phenotype or
another. For instance, patients presenting with chronic venous
ulcers suffer from chronic inflammation as a result of failing to
switch from M1 macrophages to M2 (36). On the other hand,
those suffering from classical Whipple’s disease, a result of chronic
infection caused by Tropheryma whipplei, fail to clear the infec-
tion due to the lack of inflammation and excess presence of M2
macrophages (37). Interestingly, there are also reports suggesting
that the distribution of M1 and M2 macrophages varies between
males and females. In fact, the higher incidence of asthma in
female mice was associated with higher levels of M2 macrophages
when compared to male mice (38). Since females are known to
present with higher incidence of not only asthma but also other
autoimmune diseases, it would be interesting to speculate whether
gender-associated differences in macrophage polarization might
play a role.
Finally, manipulation of macrophage polarization has already
proven to be somewhat successful clinically. Administration of
the classical M1 macrophage activator IFNγ had beneficial effects
in patients with ovarian carcinoma (39, 40). Therefore, our cur-
rent understanding of the metabolic status of differentially acti-
vated macrophages holds great potential for clinical applications,
although further research is required in order to capitalize clini-
cally on the observations made to date in both murine and human
systems.
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